466 related articles for article (PubMed ID: 27409727)
1. Relationships between serum brain-derived neurotrophic factor, plasma catecholamine metabolites, cytokines, cognitive function and clinical symptoms in Japanese patients with chronic schizophrenia treated with atypical antipsychotic monotherapy.
Hori H; Yoshimura R; Katsuki A; Atake K; Igata R; Konishi Y; Nakamura J
World J Biol Psychiatry; 2017 Aug; 18(5):401-408. PubMed ID: 27409727
[TBL] [Abstract][Full Text] [Related]
2. Blood Biomarkers Predict the Cognitive Effects of Aripiprazole in Patients with Acute Schizophrenia.
Hori H; Yoshimura R; Katsuki A; Atake K; Igata R; Konishi Y; Beppu H; Tominaga H
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28272307
[TBL] [Abstract][Full Text] [Related]
3. Effects of olanzapine on plasma levels of catecholamine metabolites, cytokines, and brain-derived neurotrophic factor in schizophrenic patients.
Hori H; Yoshimura R; Yamada Y; Ikenouchi A; Mitoma M; Ida Y; Nakamura J
Int Clin Psychopharmacol; 2007 Jan; 22(1):21-7. PubMed ID: 17159456
[TBL] [Abstract][Full Text] [Related]
4. Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia.
Goto N; Yoshimura R; Kakeda S; Moriya J; Hayashi K; Ikenouchi-Sugita A; Umene-Nakano W; Hori H; Ueda N; Korogi Y; Nakamura J
Hum Psychopharmacol; 2009 Dec; 24(8):639-45. PubMed ID: 19946939
[TBL] [Abstract][Full Text] [Related]
5. Aripiprazole altered plasma levels of brain-derived neurotrophic factor and catecholamine metabolites in first-episode untreated Japanese schizophrenia patients.
Yoshimura R; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Katsuki A; Hayashi K; Atake K; Tomita M; Nakamura J
Hum Psychopharmacol; 2012 Jan; 27(1):33-8. PubMed ID: 22213405
[TBL] [Abstract][Full Text] [Related]
6. Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients.
Yoshimura R; Ueda N; Hori H; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):256-61. PubMed ID: 20218790
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of 3-methoxy-4-hydroxyphenylglycol levels, number of hospitalization and cognitive function predicts the cognitive effect of atypical antipsychotic monotherapy in patients with acute schizophrenia.
Hori H; Yoshimura R; Katsuki A; Atake K
Int Clin Psychopharmacol; 2020 Mar; 35(2):89-97. PubMed ID: 31743230
[TBL] [Abstract][Full Text] [Related]
8. Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?
Mitoma M; Yoshimura R; Sugita A; Umene W; Hori H; Nakano H; Ueda N; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):679-85. PubMed ID: 18160197
[TBL] [Abstract][Full Text] [Related]
9. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients.
Yoshimura R; Hori H; Sugita A; Ueda N; Kakihara S; Umene W; Nakano Y; Shinkai K; Mitoma M; Ohta M; Shinkai T; Nakamura J
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1072-7. PubMed ID: 17459549
[TBL] [Abstract][Full Text] [Related]
10. Comparison of brain N-acetylaspartate levels and serum brain-derived neurotrophic factor (BDNF) levels between patients with first-episode schizophrenia psychosis and healthy controls.
Goto N; Yoshimura R; Kakeda S; Moriya J; Hayashi K; Ikenouchi-Sugita A; Umene-Nakano W; Hori H; Ueda N; Korogi Y; Nakamura J
Eur Psychiatry; 2011 Jan; 26(1):57-63. PubMed ID: 20434315
[TBL] [Abstract][Full Text] [Related]
11. Associations between five-factor model of the Positive and Negative Syndrome Scale and plasma levels of monoamine metabolite in patients with schizophrenia.
Watanabe K; Miura I; Kanno-Nozaki K; Horikoshi S; Mashiko H; Niwa S; Yabe H
Psychiatry Res; 2015 Dec; 230(2):419-23. PubMed ID: 26416588
[TBL] [Abstract][Full Text] [Related]
12. Brain-derived neurotrophic factor as a biomarker for cognitive recovery in acute schizophrenia: 12-week results from a prospective longitudinal study.
Zhang Y; Fang X; Fan W; Tang W; Cai J; Song L; Zhang C
Psychopharmacology (Berl); 2018 Apr; 235(4):1191-1198. PubMed ID: 29392373
[TBL] [Abstract][Full Text] [Related]
13. Associations of serum brain-derived neurotrophic factor with cognitive impairments and negative symptoms in schizophrenia.
Niitsu T; Shirayama Y; Matsuzawa D; Hasegawa T; Kanahara N; Hashimoto T; Shiraishi T; Shiina A; Fukami G; Fujisaki M; Watanabe H; Nakazato M; Asano M; Kimura S; Hashimoto K; Iyo M
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1836-40. PubMed ID: 21930178
[TBL] [Abstract][Full Text] [Related]
14. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia.
Kelley ME; Yao JK; van Kammen DP
Neuropsychopharmacology; 1999 Jun; 20(6):603-11. PubMed ID: 10327429
[TBL] [Abstract][Full Text] [Related]
15. Effect of risperidone on plasma catecholamine metabolites and brain-derived neurotrophic factor in patients with bipolar disorders.
Yoshimura R; Nakano Y; Hori H; Ikenouchi A; Ueda N; Nakamura J
Hum Psychopharmacol; 2006 Oct; 21(7):433-8. PubMed ID: 17029305
[TBL] [Abstract][Full Text] [Related]
16. Serum brain-derived neurotrophic factors in Taiwanese patients with drug-naïve first-episode schizophrenia: Effects of antipsychotics.
Chiou YJ; Huang TL
World J Biol Psychiatry; 2017 Aug; 18(5):382-391. PubMed ID: 27643618
[TBL] [Abstract][Full Text] [Related]
17. Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia.
Yang Y; Liu Y; Wang G; Hei G; Wang X; Li R; Li L; Wu R; Zhao J
Psychiatry Res; 2019 Mar; 273():528-536. PubMed ID: 30710808
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of brain-derived neurotrophic factor (BDNF), BDNF gene Val66Met polymorphism, or plasma catecholamine metabolites, and response to mirtazapine in Japanese patients with major depressive disorder (MDD).
Katsuki A; Yoshimura R; Kishi T; Hori H; Umene-Nakano W; Ikenouchi-Sugita A; Hayashi K; Atake K; Iwata N; Nakamura J
CNS Spectr; 2012 Sep; 17(3):155-63. PubMed ID: 22883353
[TBL] [Abstract][Full Text] [Related]
19. The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder I: a clinical naturalistic study.
Kurita M; Nishino S; Numata Y; Okubo Y; Sato T
PLoS One; 2014; 9(6):e100634. PubMed ID: 24971450
[TBL] [Abstract][Full Text] [Related]
20. Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.
Kakihara S; Yoshimura R; Shinkai K; Matsumoto C; Goto M; Kaji K; Yamada Y; Ueda N; Ohmori O; Nakamura J
Int Clin Psychopharmacol; 2005 Mar; 20(2):71-8. PubMed ID: 15729081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
